Following initial triage, some R/N accident victims will require additional testing to quantitatively determine the level of absorbed radiation. The CytoRADx Biodosimetry System is a high-throughput implementation of the proven Cytokinesis Block Micronucleus (CBMN) assay. While the assay has been accepted by many institutions around the world, including as the International Atomic Energy Agency (IAEA), as a standard method for performing quantitative biodosimetry, the traditional CBMN assay is very labor intensive and not practical to support a large-scale response following a large- scale R/N incident. Under funding provided by the Biomedical Advanced Research and Development Agency, ASELL has developed CytoRADx to address these limitations. ASELL has optimized the biomarkers and automated the CBMN assay to improve accuracy and expand the assessable dose range. Using existing equipment and techniques commonly found in clinical laboratories and reagents provided in a standardized kit, CytoRADx will provide emergency preparedness to respond as scale.